Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.

The extrinsic coagulation pathway is activated when circulating factor VII (FVII) gains access to tissue factor (TF) exposed as a consequence of vascular injury. Increasing evidence indicates that this TF-dependent activation of the coagulation plays an important role in the pathophysiology of intravascular thrombus formation. In the present study, we tested the effects of recombinant human, active site-blocked activated FVII (FVIIai) in a rabbit model of carotid artery thrombosis. Cyclic flow variations (CFVs), due to recurrent thrombus formation, were obtained in stenotic rabbit carotid arteries with endothelial injury. Carotid blood flow velocity was measured by a Doppler flow probe. After 30 minutes of CFVs, the animals received FVIIai (100 microg x kg(-1) x min(-1) intracarotid infusion for 10 minutes, n=9). If CFVs were abolished, animals were followed for 30 additional minutes, after which recombinant human activated FVII (FVIIa) was infused into the carotid artery (100 microg x kg(-1) x min(-1) for 10 minutes) to determine whether FVIIai could be displaced from TF by FVIIa, thus restoring CFVs. To establish the duration of action of FVIIai, an additional group of animals received FVIIai at the same dose as above, and after CFVs were inhibited, they were followed until CFVs were restored or for up to 6 hours. To determine whether CFVs could be restored by epinephrine after their abolition with FVIIai, increasing doses of epinephrine were administered to a third group of 6 animals. FVIIai abolished CFVs in 8 of 9 rabbits (P<.01). This effect was reversible, as FVIIa administration restored CFVs in all animals. Prothrombin times and activated partial thromboplastin times did not change significantly throughout the study. One single 10-minute infusion exerted complete antithrombotic effects for at least 6 hours, despite the fact that at this time point, plasma FVIIai levels were well below threshold concentrations. Epinephrine restored CFVs in 3 of 6 animals in which CFVs were inhibited by FVIIai. FVIIai exerts potent antithrombotic effects in this model; these effects were prolonged even after FVIIai was almost completely cleared from the circulation, probably as a result of the tight binding of FVIIai to TF. Thus, FVIIai might represent an antithrombotic substance of potential interest.

[1]  P. Freskgård,et al.  Incorporation of an Active Site Inhibitor in Factor VIIa Alters the Affinity for Tissue Factor* , 1997, The Journal of Biological Chemistry.

[2]  M. Chiariello,et al.  Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. , 1996, Circulation.

[3]  J. Sevinsky,et al.  Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor- dependent coagulation pathway , 1996, The Journal of cell biology.

[4]  S. Hanson,et al.  Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. , 1996, Haemostasis.

[5]  M. Chiariello,et al.  Aurintricarboxylic Acid Reduces Platelet Deposition in Stenosed and Endothelially Injured Rabbit Carotid Arteries more Effectively than other Antiplatelet Interventions , 1995, Thrombosis and Haemostasis.

[6]  K. Channon,et al.  Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. , 1995, Circulation.

[7]  E. Topol,et al.  Direct thrombin inhibitors in cardiovascular medicine. , 1994, Circulation.

[8]  J. Schullek,et al.  Key ligand interface residues in tissue factor contribute independently to factor VIIa binding. , 1994, The Journal of biological chemistry.

[9]  S. Iwanaga,et al.  Identification of regions of bovine factor VII essential for binding to tissue factor. , 1994, The Journal of biological chemistry.

[10]  J. Schullek,et al.  Mutational mapping of functional residues in tissue factor: identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. , 1994, Biochemistry.

[11]  M. Chiariello,et al.  A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. , 1994, Circulation research.

[12]  E. Topol,et al.  Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast , 1993, Circulation.

[13]  M. Davies,et al.  Atherosclerosis: what is it and why does it occur? , 1993, British heart journal.

[14]  M. Condorelli,et al.  Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. , 1992, Circulation research.

[15]  S. Rapaport,et al.  Initiation and regulation of tissue factor-dependent blood coagulation. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[17]  M. Chiariello,et al.  Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation. , 1992, Thrombosis and haemostasis.

[18]  W. Novotny,et al.  Regulation of coagulation by a multivalent Kunitz-type inhibitor. , 1990, Biochemistry.

[19]  J. Eidt,et al.  Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.

[20]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Benedict,et al.  Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. , 1989, Circulation.

[22]  L. Thim,et al.  Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. , 1988, Biochemistry.

[23]  K. Williams,et al.  Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[24]  V. Ploplis,et al.  Initiation of the extrinsic pathway of coagulation. Association of factor VIIa with a cell line expressing tissue factor. , 1987, The Journal of biological chemistry.

[25]  T. Edgington,et al.  Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade , 1987, Cell.

[26]  P. Théroux,et al.  Fibrinopeptide A and platelet factor levels in unstable angina pectoris. , 1987, Circulation.

[27]  L. Hillis,et al.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.